<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01268358</url>
  </required_header>
  <id_info>
    <org_study_id>rhLAMAN-02</org_study_id>
    <secondary_id>2010-022084-36</secondary_id>
    <nct_id>NCT01268358</nct_id>
  </id_info>
  <brief_title>Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis</brief_title>
  <official_title>A Single Center, Open-label, Dose Escalation Study of the Safety and Pharmacokinetics of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) for the Treatment of Patients With Alpha-mannosidosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zymenex A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, dose escalation study of patients with&#xD;
      alpha-mannosidosis. 10 patients will be enrolled in this study receiving intravenous&#xD;
      infusions of Lamazym. In order to avoid development of delayed hypersensitivity all patients&#xD;
      will continue weekly treatment at the designated dose until the Safety Committee approves&#xD;
      transfer to the rhLAMAN-03 protocol.&#xD;
&#xD;
      It is the hypothesis that Lamazym is safe to use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety profile of rhLAMAN (Lamazym)</measure>
    <time_frame>1-5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the PK profile of rhLAMAN (Lamazym) in patients with alpha-mannosidosis as measured by rhLAMAN levels in plasma</measure>
    <time_frame>1 dosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To collect baseline measurements that are to be used for efficacy evaluation in the following trial (rhLAMAN-03)</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Alpha Mannosidosis</condition>
  <arm_group>
    <arm_group_label>Lamazym 6.25</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamazym 12.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamazym 25</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamazym 50</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamazym 100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamazym</intervention_name>
    <description>Lamazym, ERT, infusion weekly</description>
    <arm_group_label>Lamazym 100</arm_group_label>
    <arm_group_label>Lamazym 12.5</arm_group_label>
    <arm_group_label>Lamazym 25</arm_group_label>
    <arm_group_label>Lamazym 50</arm_group_label>
    <arm_group_label>Lamazym 6.25</arm_group_label>
    <other_name>rhLAMAN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must have a confirmed diagnosis of alpha-mannosidosis as defined by&#xD;
             alpha-mannosidase activity &lt; 10% of normal activity in blood leukocytes&#xD;
&#xD;
          2. The patient must have an age at the time of screening ≥ 5 year and ≤ 20 years&#xD;
&#xD;
          3. The patient must have physical ability to perform 6-minutes walk test (6MWT), 3&#xD;
             minute-stair climb test (3MSCT) and pulmonary lung function test (spirometry, body&#xD;
             plethysmography).&#xD;
&#xD;
          4. The patient must have the ability to mentally cooperate in the cognitive and motor&#xD;
             function tests&#xD;
&#xD;
          5. The patient must have the ability to hear and follow a request. Hearing aids can be&#xD;
             worn.&#xD;
&#xD;
          6. Patient or patient's legally authorized guardian(s) must provide signed, informed&#xD;
             consent prior to performing any study-related activities (trial-related activities are&#xD;
             any procedures that would not have been performed during normal management of the&#xD;
             subject)&#xD;
&#xD;
          7. The patient and his/her guardian(s) must have the ability to comply with the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient cannot walk without support.&#xD;
&#xD;
          2. Presence of known chromosomal abnormality and syndromes affecting psychomotor&#xD;
             development, other than alpha-mannosidosis&#xD;
&#xD;
          3. History of bone marrow transplantation&#xD;
&#xD;
          4. Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal&#xD;
             disease or other medical conditions that, in the opinion of the Investigator, would&#xD;
             preclude participation in the trial&#xD;
&#xD;
          5. Presence of an ECHO with abnormalities within half a year that, in the opinion of the&#xD;
             Investigator, would preclude participation in the trial&#xD;
&#xD;
          6. Any other medical condition or serious intercurrent illness, or extenuating&#xD;
             circumstance that, in the opinion of the investigator, would preclude participation in&#xD;
             the trial&#xD;
&#xD;
          7. Pregnancy&#xD;
&#xD;
          8. Psychosis within the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan M. Lund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Genetics, Juliane Marie Centre, Region Hovedstaden, Copenhagen University hospital, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Fogh</last_name>
    <role>Study Chair</role>
    <affiliation>Zymenex A/S</affiliation>
  </overall_official>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022084-36</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <reference>
    <citation>Borgwardt L, Thuesen AM, Olsen KJ, Fogh J, Dali CI, Lund AM. Cognitive profile and activities of daily living: 35 patients with alpha-mannosidosis. J Inherit Metab Dis. 2015 Nov;38(6):1119-27. doi: 10.1007/s10545-015-9862-4. Epub 2015 May 28.</citation>
    <PMID>26016802</PMID>
  </reference>
  <results_reference>
    <citation>Borgwardt L, Dali CI, Fogh J, Månsson JE, Olsen KJ, Beck HC, Nielsen KG, Nielsen LH, Olsen SO, Riise Stensland HM, Nilssen O, Wibrand F, Thuesen AM, Pearl T, Haugsted U, Saftig P, Blanz J, Jones SA, Tylki-Szymanska A, Guffon-Fouiloux N, Beck M, Lund AM. Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study. J Inherit Metab Dis. 2013 Nov;36(6):1015-24. doi: 10.1007/s10545-013-9595-1. Epub 2013 Mar 14.</citation>
    <PMID>23494656</PMID>
  </results_reference>
  <results_reference>
    <citation>Borgwardt L, Stensland HM, Olsen KJ, Wibrand F, Klenow HB, Beck M, Amraoui Y, Arash L, Fogh J, Nilssen Ø, Dali CI, Lund AM. Alpha-mannosidosis: correlation between phenotype, genotype and mutant MAN2B1 subcellular localisation. Orphanet J Rare Dis. 2015 Jun 6;10:70. doi: 10.1186/s13023-015-0286-x.</citation>
    <PMID>26048034</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 29, 2010</study_first_submitted>
  <study_first_submitted_qc>December 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2010</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannosidase Deficiency Diseases</mesh_term>
    <mesh_term>alpha-Mannosidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

